ACRUX’S DR RICHARD TREAGUS: CRANKING THE HANDLE
WHY DR RICHARD TREAGUS IS LEAVING ACRUX
AVEXA’S DR JULIAN CHICK: A BIOTECH PARADIGM
BIONOMICS' DR DEBORAH RATHJEN: 'THIS IS JUST THE BEGINNING'
CHEMEQ’S DAVID WILLIAMS: FROM $8 TO 35c … AND BACK?
CIRCADIAN'S DR MEGAN BALDWIN SHARPENS FOCUS
CLINUVEL’S DR PHILIPPE WOLGEN: ‘CUV1647 NOT COSMETIC NOT SUNBLOCK’
CSIRO’S DR GRAEME WOODROW: ALL HAIL THE CHIEF
EVOGENIX’S DR MERILYN SLEIGH: ‘KEEP IT SIMPLE’
GBS VENTURE PARTNERS' DR GEOFF BROOKE: BUILDING AUSTRALIAN MEDICAL TECHNOLOGIES
GENETIC TECHNOLOGIES' DR MERVYN JACOBSON: ‘ONE DECENT LICENCE AND WE’RE PROFITABLE’
GENETIC TECHNOLOGIES DR PAUL MACLEMAN: THE HOTTEST SEAT IN BIOTECH
GLAXOSMITHKLINE'S DEBORAH WATERHOUSE: NO ORDINARY BOSS
IMPEDIMED'S GREG BROWN: 'BRISBANE TO BASLE AND BACK'
LEON SERRY: RETIREMENT STARTS WITH A 12-HOUR DAY
MESOBLAST'S PROF SILVIU ITESCU: HE'S THE BOSS
METABOLIC’S DR ROLAND SCOLLAY WON’T LOOK BACK
MIPS' PROF BILL CHARMAN: FROM PHARMACY COLLEGE TO BIOTECH CRUCIBLE - PLUS
NOVOGEN’S CHRIS NAUGHTON: ‘THE LONG WAIT FOR PHASE III RESULTS’
PEPLIN’S MICHAEL ALDRIDGE: ‘CREDIBILITY IS CRITICAL’
PEPLIN'S TOM WIGGANS: THIS ISN'T CANCER ANYMORE, TOTO
PEPTECH’S DR JOHN CHIPLIN: ‘DOMAINS ARE THE CROWN JEWELS’
PROTEOME STEPHEN PORGES: TESTING CANCER
STARPHARMA'S DR JACKIE FAIRLEY: LEADER OF THE DENDRIMER PACK
STEM CELL SCIENCES DR PETER MOUNTFORD: 'PLAN R&D OR LOSE 20 YEARS'
VICTORIA'S INNOVATION MINISTER MARTIN PAKULA TALKS BIOTECH
WEHI'S PROF DOUG HILTON: EVOLUTION & VERY INTELLIGENT DESIGN